Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 336 results for "erbitux"

Eli Lilly and Given Buy Rating at SunTrust (LLY)

BMS, Lilly's targeted drug Erbitux gets new FDA nod

Erbitux from Bristol-Myers Squibb ($BMY) and Eli Lilly ($LLY) has received a new first-line approval for targeted use against colorectal cancer. The agency OK comes along with approval for a companion diagnostic test to identify patients without the ... FiercePharma, 4 days ago
Eli Lilly and Lifted to Buy at Zacks (LLY) SleekMoney, 1 week ago

Technavio Says the Prevalence of Colorectal Cancer Will Drive the Global Colorectal Cancer Drugs Market Through 2019

LONDON--(EON: Enhanced Online News The major biologics used for treating colorectal cancer include Erbitux (cetuximab), Zaltrap (ziv-Aflibercept), Avastin (bevacizumab), and Vectibix (panitumumab) The new industry analysis report highlights the ...
 EON: Enhanced Online News1 month ago Second-line cetuximab plus FOLFOX extends PFS in wild-type metastatic colorectal cancer  Orthopedics Today2 weeks ago

Global & USA Cancer Immunotherapy Market Analysis to 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T

-Cell Therapy, PD-1/PD-L1 inhibitors, & Others GLOBAL & USA CANCER IMMUNOTHERAPY MARKET ANALYSIS TO 2020: Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) ...
 MoneyShow.com1 day ago

World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025

LONDON , July 30, 2015 /PRNewswire/ -- Cancer Treatments - Your New Guide to that Market, its R&D and Sales Potentials Do you want to assess the future of cancer-treating medicines ? Visiongai n's new report gives you revenue predictions for that ...
 ProfitQuotes.com2 days ago New lung cancer therapy gives 'real hope to patients'  i24news1 month ago
Jutia Group

Market Update: Bristol-Myers Squibb Company (NYSE:BMY) Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.

[Business Wire] NEW YORK & TOKYO(BUSINESSWIRE) Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,Kyowa Hakko Kirin) and Bristol-Myers Squibb Company (NYSE:BMY, Bristol-Myers Squibb) today announced that the companies have … Read more on this. ...
 Jutia Group2 days ago Company Update: Bristol-Myers Squibb Company (NYSE:BMY) Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development  Jutia Group1 week ago Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat fixed-dose combination) for the Treatment of HIV-1 Infection in Adults  Jutia Group2 weeks ago

Research and Markets: Global Colorectal Cancer Drugs Market 2015-2019

Research and Markets ( ) has announced the addition of the "Global Colorectal Cancer Drugs Market 2015-2019" report to their offering. The global colorectal ...
 4 Traders4 days ago Global Colorectal Cancer Drugs Market 2015-2019 - The Dominance of Biologics  PR Newswire2 days ago

Eli Lilly and Receives $86.29 Average Price Target from Analysts (NYSE:LLY)

Eli Lilly and (NYSE:LLY) has earned a consensus recommendation of Buy from the twenty-two ratings firms that are covering the stock, Analyst Ratings.Net reports . Eight analysts have rated the stock with a hold rating and fourteen have assigned a ...
 SleekMoney3 days ago Eli Lilly and Receives $81.24 Average PT from Brokerages (NYSE:LLY)  SleekMoney1 month ago

Oncobiologics allies with inVentiv on biosimilars development

Oncobiologics and the CRO inVentiv Health have joined forces to develop a slate of biosimilars . The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira , Rituxan , Avastin , Herceptin and Erbitux . A variety of new partnerships ...
 FierceBiotech3 days ago Oncobiologics raises $31M for a PhIII biosimilar play against Humira  FierceBiotech5 days ago

Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer

Patrick Soon-Shiong made several fortunes based on his understanding of cancer and drug development, most recently in today's multibillion-dollar IPO for NantKwest. And now he plans to put the IPO money to use in pursuit of a new strategy in ...
 FierceBiotech3 days ago NantKwest on deck for IPO  TeleTrader.com1 week ago
Pettinga Financial Advisors

Lilly Reports Second-Quarter 2015 Results, Revises 2015 Financial Guidance

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2015. $ in millions, except per share data Second Quarter % 2015 2014 Change Revenue - ...
 FierceBiotech3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - erbitux
Get updated on latest news & your favorite topics right in your inbox!
More     Less